严重肢体缺血少数族裔患者经自体细胞治疗获得的截肢风险降低与白人相当
该研究为MOBILE随机双盲多中心试验的事后分析,按族裔分层比较无血运重建选择的严重肢体缺血(CLI)患者接受浓缩骨髓穿刺液(cBMA)注射的结局。少数族裔患者1年无截肢生存率为80%,cBMA组少数族裔为89%、白人为77%;非劣效性检验确认主要截肢减少方面白人与少数族裔无差异,但无截肢生存方面未能确认非劣效性。
要点
- MOBILE试验中37例少数族裔CLI患者按3:1随机接受cBMA(28例)或安慰剂(9例)。
- cBMA组少数族裔1年无截肢生存率89%,白人为77%。
- 主要截肢减少方面非劣效性成立,无截肢生存方面非劣效性未确认。
核心结论
- MOBILE试验事后分析表明,无血运重建选择的少数族裔CLI患者接受cBMA干预在主要截肢预防这一治疗终点上非劣效于白人。
- cBMA代表一种新的治疗模式,作者认为应针对血运重建选择差、因进展性CLI面临截肢的少数族裔患者进行探索。
研究设计与样本
- 随机双盲多中心MOBILE试验治疗组的事后分析,按族裔分层评估人口学、合并症和结局。
- 37例无合适血运重建选择的少数族裔CLI患者(非裔美国人、西班牙裔、其他)按3:1随机接受cBMA(28例)或安慰剂(9例)。
- 主要终点为1年无截肢生存,治疗终点为主要截肢;非劣效性分析的界值设定为历史报告的 hazard ratio。
主要发现
- 治疗组1年随访总体无截肢生存率为80%。
- 28例随机接受cBMA的少数族裔患者1年无截肢生存率为89%,白人为77%。
- 24例非裔美国人中22例(92%)在1年随访时无截肢生存。
- 非劣效性检验确认白人与接受cBMA的少数族裔在主要截肢减少方面无差异,但无截肢生存方面未能确认非劣效性。
- 次要终点(血管生活质量、肢体疼痛、踝肱指数、趾肱指数、经皮氧测定、6分钟步行试验)未见有利于接受cBMA白人的显著差异。
临床怎么用
- 作者认为cBMA代表一种新的治疗模式,应针对血运重建选择差、因进展性CLI面临截肢的少数族裔患者进行探索。
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Ethnic minorities (nonwhites) with critical limb ischemia (CLI) have historically performed worse compared with whites with regard to major amputation risk reduction and amputation-free survival (AFS) after peripheral vascular intervention. This post hoc analysis was completed to determine whether this precedent also extended to treatment of CLI without a suitable revascularization option with intramuscular injections of concentrated bone marrow aspirate (cBMA). METHODS: The treatment arm of the randomized, double-blind, multicenter MarrowStim PAD Kit for the Treatment of Critical Limb Ischemia in Subjects with Severe Peripheral Arterial Disease (MOBILE) trial was stratified by ethnicity and evaluated for demographics, comorbidities, and outcomes. The primary and therapeutic end point was 1-year AFS and major amputation, respectively. Noninferiority analysis was performed with the margin set at historically reported hazard ratios. RESULTS: Thirty-seven minority (African American, Hispanic, other) CLI patients (9 placebo, 28 cBMA) with no suitable revascularization option were randomized to cBMA or placebo at a 3:1 ratio during the MOBILE trial. At 1-year follow-up for the treatment group, overall AFS was 80%. Of the 28 minority patients randomized to cBMA intervention, an 89% AFS rate was observed compared with 77% in whites. Specifically, 22 of 24 (92%) African Americans survived amputation free at 1-year follow-up. Noninferiority testing confirmed no difference between whites and the ethnic minority treated with cBMA with respect to major amputation reduction; however, noninferiority could not be confirmed with regard to AFS. No significant differences favoring whites treated with cBMA were noted in the secondary end points of vascular quality of life, limb pain, ankle-brachial index, toe-brachial index, transcutaneous oximetry, and 6-minute walk testing. CONCLUSIONS: This post hoc analysis of the MOBILE trial demonstrates noninferiority of cBMA intervention in minorities with no-option CLI for the therapeutic end point of major amputation prevention. cBMA represents a novel treatment paradigm and should be explored for minorities with poor revascularization options who face impending amputation secondary to progressive CLI.
引用
- Wang SK, Green LA, Gutwein AR, et al. Ethnic minorities with critical limb ischemia derive equal amputation risk reduction from autologous cell therapy compared with whites. J Vasc Surg. 2018. PMID: 29503004. doi:10.1016/j.jvs.2017.11.088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。